Melanoma Research最新文献

{"title":"Integrating neutrophils, lymphocytes and eosinophils: development and validation of the NLE Index in ICI-treated metastatic melanoma.","authors":"Fatma Pinar Açar, Caner Acar, Haydar Çağatay Yüksel, Gökhan Şahin, Bilge Bayir, Irem Özdemir, Tuğba Mermer, Burçak Karaca","doi":"10.1097/CMR.0000000000001060","DOIUrl":"10.1097/CMR.0000000000001060","url":null,"abstract":"<p><p>Prognosis for metastatic melanoma patients treated with immune checkpoint inhibitors (ICIs) remains heterogeneous. Although neutrophil-to-lymphocyte ratio (NLR) and neutrophil-to-eosinophil ratio (NER) are established markers, we hypothesized a neutrophil-to-lymphocyte-times-eosinophil (NLE) index would offer superior stratification. We analyzed 194 metastatic melanoma patients receiving ICIs, divided into training ( n  = 129) and validation ( n  = 65) cohorts. An optimal NLE cutoff categorized patients as NLE-low or NLE-high. Survival outcomes and objective response rate (ORR) were assessed using Kaplan-Meier, Cox regression, and logistic regression. Predictive accuracy of NLE, NLR, and NER was compared. Median overall survival was significantly longer in NLE-low versus NLE-high patients (training: 31.3 versus 6.9 months; P  = 0.011; validation: 33.5 versus 9.1 months; P  = 0.019). Median progression-free survival also improved significantly in NLE-low patients (training: 10.6 versus 3.1 months; P  = 0.029; validation: 13.7 versus 3.9 months; P  = 0.012). ORR was higher in NLE-low groups (training: 46.0% versus 13.2%; P  < 0.001; validation: 43.6% versus 18.2%; P  = 0.078). NLE demonstrated superior predictive accuracy compared with NLR and NER. The NLE index outperforms NLR and NER in predicting survival and response in metastatic melanoma patients treated with ICIs, providing a practical clinical tool.</p>","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"380-389"},"PeriodicalIF":1.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144960916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Late peritoneal carcinomatosis from cutaneous melanoma mimicking ovarian cancer.","authors":"Stefano Fucina, Lucia Lerda, Anna Del Fabro, Claudio Reato, Emilio Lucia, Nicolò Clemente, Fabio Puglisi, Michele Bartoletti, Antonio Palumbo, Vincenzo Canzonieri, Antonino Ditto","doi":"10.1097/CMR.0000000000001064","DOIUrl":"10.1097/CMR.0000000000001064","url":null,"abstract":"<p><p>Peritoneal carcinomatosis represents an exceptionally rare metastatic pattern of cutaneous malignant melanoma, occurring in fewer than 1% of cases with distant spread and typically within the first few years after primary treatment. This report presents an unusual case with a markedly prolonged disease-free interval, clinically mimicking advanced ovarian carcinoma. We report the case of a 53-year-old woman treated more than 10 years ago for stage IIB nodular melanoma with surgery and adjuvant therapy. The patient presented with progressive abdominal bloating. Imaging revealed bilateral adnexal masses, ascites, peritoneal carcinomatosis, and multiple pulmonary nodules, initially suggestive of advanced ovarian cancer. Diagnostic laparoscopy demonstrated diffuse peritoneal lesions with an atypical yellowish, soft, and nonpigmented appearance. Histology and immunohistochemistry confirmed metastatic melanoma. This case is among the few reports of peritoneal carcinomatosis from melanoma after more than a decade of remission. The prolonged disease-free interval and atypical presentation underline the heterogeneous behavior of melanoma and the need for long-term vigilance and multidisciplinary evaluation.</p>","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"429-431"},"PeriodicalIF":1.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145033702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of surgical modalities for stage 0 to stage II acral lentiginous melanoma: a National Cancer Database study.","authors":"Reagan F Blohowiak, Nicole W Welch, Bryce W Rigden, Rahul M Varman, Peter T Silberstein, Marco J DiBlasi","doi":"10.1097/CMR.0000000000001046","DOIUrl":"10.1097/CMR.0000000000001046","url":null,"abstract":"<p><p>Wide local excision (WLE) is the standing surgical choice for acral lentiginous melanoma (ALM), yet research is scarce in evaluating other surgical options for ALM and its recurrence rates remain two to five times more likely than other melanoma subtypes. This study evaluates the overall survival outcomes associated with different surgical modalities in patients with stage 0-II ALM. This retrospective cohort study surveyed the National Cancer Database from 2004 to 2021 for International Classification of Diseases-10 codes specific for all skin structures with histologically confirmed ALM for stage 0-II patients. Using IBM SPSS, statistical analyses were conducted via variable frequency with crosstabulations and Chi-squared tests, Kaplan-Meier survival curves with log-rank pairwise comparisons, and Cox proportional hazards regression models. Data for 6737 patients showed significantly greater overall survival for biopsy followed by gross excision (BFGE) than WLE [median overall survival = 204.8 months ( P  < 0.001); hazard ratio = 0.77 (95% confidence interval, 0.68-0.87)]. Median overall survival for WLE was 181.6 months. Cross analysis of Breslow depth (BD) with surgical procedures revealed the majority (21.8%) of WLEs were completed for lesions with a BD of 0.1-5 mm followed by 16.8% for lesions greater than 3 cm ( P  < 0.001). Crossanalysis of surgical margins of the primary site with surgical procedures, showed no residual tumor in 92.1% of all BFGE patients, which is 3.7% and 3.3% less patients than major amputation and WLE. This study highlights significant differences across ALM surgery options, suggesting each modality has their own niche and BFGE should be investigated further.</p>","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"347-351"},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144216323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rurality as a predictor of melanoma stage and treatment in Indiana: a retrospective cohort study.","authors":"Gloria R Xue, Marie Clark, James E Slaven, Syril Keena T Que","doi":"10.1097/CMR.0000000000001044","DOIUrl":"https://doi.org/10.1097/CMR.0000000000001044","url":null,"abstract":"","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":"35 5","pages":"366-367"},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144960962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Upregulation of SFTPC gene expression is associated with disease progression and worse survival outcomes in human skin melanomas.","authors":"Yuelong Chai, Jiang Zhao, Xiangwei Wang, Benyi Li","doi":"10.1097/CMR.0000000000001051","DOIUrl":"10.1097/CMR.0000000000001051","url":null,"abstract":"<p><p>The surfactant protein-C (SFTPC) gene encodes a hydrophobic pulmonary surfactant protein essential for lung function and homeostasis. While primarily associated with lung diseases, emerging evidence suggests its potential involvement in human cancers. In addition, SFTPC expression was also found in human skin cells, however, its expression profile in cutaneous melanoma is unknown. In this study, we analyzed expression profiles of SFTP family genes including SFTPA1/2 , SFTPB , SFTPC , and SFTPD in human skin melanoma tissues. Our analysis revealed that SFTPC expression was the predominant SFTP gene and was associated with disease progression, including tumor stage, Clark level, and Breslow depth. High levels of SFTPC expression in skin melanoma tissues were significantly associated with patient survival outcomes including overall and disease-specific survival. The associations were specifically dictated in aggressive tumors, suggesting a potential role of SFTPC expression in melanoma progression. Interestingly, SFTPC expression was negatively correlated with T-helper cell infiltration in skin melanoma tissues. Gene enrichment analysis also indicated that SFTPC expression was in parallel with elevated expressions of mitochondrial energy biosynthesis-related genes and reduced IgE/IgG-mediated immunity-related genes. In conclusion, SFTPC upregulation is associated with disease progression and patient survival outcomes, possibly through enhancing ATP overproduction and suppressing antitumor immunity.</p>","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"317-327"},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Programmed death ligand-1 PET imaging in patients with melanoma: a pilot study.","authors":"Neeta Pandit-Taskar, Audrey Mauguen, Denise Frosina, Achim Jungbluth, Klaus J Busam, Serge Lyashchenko, Jazmin Schwartz, Parisa Momtaz, Allison Betof Warner, James W Smithy, Alexander N Shoushtari, Margaret K Callahan, Paul B Chapman, Michael A Postow","doi":"10.1097/CMR.0000000000001050","DOIUrl":"10.1097/CMR.0000000000001050","url":null,"abstract":"<p><p>Programmed death ligand-1 (PD-L1) is an inducible protein heterogeneously expressed in melanoma. Assessment of PD-L1 expression is challenging and standard immunohistochemistry (IHC) requires biopsies and cannot capture heterogeneity of expression. Noninvasive imaging methods provide evaluation of expression across lesions in the body. We conducted a prospective pilot trial with PD-L1 PET imaging with [ 18 F]-BMS-986229 as a noninvasive approach to assess PD-L1 expression across lesions, in 10 patients with advanced melanoma, longitudinally during treatment with nivolumab and ipilimumab. PET imaging was performed at baseline and at 6 weeks after initiation of treatment. We examined the relationship of PD-L1 PET uptake to radiographic clinical response. [ 18 F]-BMS-986229 uptake was variably seen across lesions in patients at baseline. All patients showed positive uptake in lesions at baseline PET with a median SUV max of 3.6 (range: 1.7-8.6). PD-L1 PET SUV max decreased in all but two lesions 6 weeks after treatment initiation. Four of five patients had a mean (SUV max ) greater than or equal to 3.00 in Response Evaluation Criteria in Solid Tumors (RECIST) evaluable lesions at baseline, and all had a RECIST response while all progressors ( n  = 3) had baseline PD-L1 mean SUV max less than or equal to 2.60. A higher lesional baseline SUV max was associated with greater individual lesion reduction during treatment. The PD-L1 uptake in lesions showed a low correlation with baseline PD-L1 by IHC. In this small pilot study, PD-L1 PET imaging using [ 18 F]-BMS-986229 showed feasibility in noninvasively assessing lesion uptake and PD-L1 heterogeneity in patients receiving combination immunotherapy. Future exploration of this tracer in larger patient cohorts is necessary to delineate its use in managing immunotherapy treatments.</p>","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"328-338"},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12393058/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144485036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiple melanoma, ichthyosis, and juvenile cataracts in a patient with a germline mutation in CDKN2A: pure coincidence or related association?","authors":"Vincenzo De Giorgi, Federica Fazzari, Giovanni Cecchi, Gabriella Perillo, Biancamaria Zuccaro, Piero Covarelli","doi":"10.1097/CMR.0000000000001058","DOIUrl":"https://doi.org/10.1097/CMR.0000000000001058","url":null,"abstract":"","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":"35 5","pages":"367-368"},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144960983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perioperative neutrophil-to-lymphocyte ratio in patients with melanoma: a pilot study assessing surgical stress after sentinel lymph node biopsy.","authors":"Karoline Assifuah Kristjansen, Lene Birk-Sørensen, Marie Louise Bønnelykke-Behrndtz","doi":"10.1097/CMR.0000000000001052","DOIUrl":"10.1097/CMR.0000000000001052","url":null,"abstract":"<p><p>Surgical stress is gaining increasing focus in surgical oncology due to its impact on complications, prognosis, and survival. The neutrophil-to-lymphocyte ratio (NLR) is a recognized biomarker reflecting inflammation and immune response, key aspects of surgical stress. Sentinel lymph node biopsy (SLNB) and wide local excision (WLE) are considered minimally invasive procedures used in the management of melanoma. Yet, the surgical stress response of WLE and SLNB remains unexplored. This study aims to investigate perioperative changes in the NLR as a marker of surgical stress in patients with melanoma undergoing WLE and SLNB. This prospective pilot study investigated NLR as a marker of surgical stress in patients ( n = 20) with melanoma undergoing WLE and SLNB. NLR was calculated from the plasma differential count and measured preoperatively and at 2 and 6 h postoperatively. Surgical stress was categorized into four groups according to the NLR values: No stress, mild, moderate, and severe stress. Paired t -tests tested differences between time points. Mean NLR increases from 1.94 (±0.86) preoperatively to 9.5 (±4.39) at 2 h ( P < 0.001) and further increases to 16.04 (±11.11) at 6 h ( P = 0.02) postoperatively. This increase reflects a shift from no systemic stress (NLR: 1-3) to a moderate (NLR: 8-18) response, approaching severe thresholds. Changes in NLR are driven by significant neutrophilia and lymphocytopenia. Despite minor procedures, WLE and SLNB elicit a substantial surgical stress response. NLR may serve as a valuable biomarker for monitoring surgical stress in melanoma surgery, with potential implications for surgical and oncologic outcomes.</p>","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"339-343"},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postimmunotherapy antiglial fibrillary acidic protein encephalomyelitis after adjuvant pembrolizumab for melanoma.","authors":"Inès Berkaoui, Linda Zourdani, Raphaël Janela-Lapert","doi":"10.1097/CMR.0000000000001048","DOIUrl":"10.1097/CMR.0000000000001048","url":null,"abstract":"<p><p>Pembrolizumab is an immune checkpoint inhibitor targeting programmed cell death protein 1 , used for stage IIB/IIC melanoma. While effective, pembrolizumab can lead to immune-mediated toxicities in various systems; however, nervous system effects are less well-documented. We report the case of a 34-year-old man who developed delayed immune-mediated encephalomyelitis with antiglial fibrillary acidic protein (GFAP) antibodies after completing nine cycles of adjuvant pembrolizumab for stage IIC melanoma. Four months posttreatment, he presented with neurological symptoms, including ataxic gait, sensory deficits in the lower limbs, and urinary retention. Imaging revealed extensive myelitis and encephalitis in the spinal cord and posterior fossa. The etiological evaluation was negative except for the presence of anti-GFAP antibodies in the cerebrospinal fluid. Treatment with high-dose corticosteroids led to significant improvement. This case represents the first reported instance of postimmunotherapy encephalomyelitis with anti-GFAP antibodies following pembrolizumab treatment. Although rare, this is a serious adverse event requiring careful monitoring and early multidisciplinary management.</p>","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"357-360"},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144216326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful use of nivolumab and relatlimab as salvage therapy for metastatic uveal melanoma.","authors":"Ritwick S Mynam, Nandakumar Menon, Alexander Birbrair, Vincent T Ma","doi":"10.1097/CMR.0000000000001045","DOIUrl":"10.1097/CMR.0000000000001045","url":null,"abstract":"<p><p>Identification of effective systemic therapies for the treatment of metastatic uveal melanoma remains an ongoing challenge. While immune checkpoint inhibitors are frequently used to treat this disease, response rates and survival outcomes remain poor. In this case report, we present two heavily pretreated patients with metastatic uveal melanoma who had robust responses to combination nivolumab (PD-1 inhibitor) with relatlimab (LAG-3 inhibitor) as salvage treatment. We highlight the ongoing research of the uveal melanoma tumor immune microenvironment and the potential role of LAG-3 inhibition as an effective treatment strategy.</p>","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"352-356"},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12212964/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144216327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}